Labskin scientists cloned 16 swabs of skin from the cheeks of healthy volunteers into 54 Labskin test subjects to allow sequencing of microbial DNA for the identification and quantification of the bacterial microbiome isolated and pooled together. The live bacteria, virus and fungi (microbiota) was consistant on all 54 test subjects for up to 7 days in the Labskin laboratories in York, UK.
The LabskinAI virtual model aggregated and analysed the bacterial microbiome data, extracted from each sample, and after eliminating false or anomalous readings, provided test results within a range of ±10% of the human volunteers’ control skin from which it was initially cloned..
The results of this study validate Labskin’s ability to undertake multiple clinical trial and skincare product testing, in parallel, on the cloned human skin microbiome, that is as close to the original microbiome of a human test subject, without the need for human volunteers after initial cloning takes place. This further allows multiple skincare products or topical drug samples to be tested on the same subject, at the same time, thus substantially reducing product development time, clinical error and clinical trial supervision costs.
By Deepverge – September 5th, 2019
Exclusive webinar in English 👉 Click here to watch the replay Discover the latest evaluation…
Georgina Caldwell 28 February 2025 THE WHAT? Shiseido’s patented, proprietary optical clearing technique, which makes skin…
The global beauty industry is undergoing a transformative shift as consumers increasingly prioritize transparency, sustainability,…